What МИГ 400 Treats: Main Uses and Benefits

МИГ 400 is commonly used to provide supportive symptomatic relief by addressing three primary domains: pain, inflammation, and fever. It is relevant in conditions where functional stability becomes affected and offers symptomatic assistance in situations where symptoms interfere with daily functioning.

This medication is applied in scenarios where additional management of discomfort is required for symptoms related to inflammatory or irritative states and episodic changes. Its clinical relevance is broad, commonly used across conditions presenting with acute episodes such as headaches, dental pain, muscular aches, menstrual cramps (dysmenorrhea), arthritis, sprains, and fever associated with the cold or flu.

The primary benefit is that it supports the patient during difficult episodes by easing distress and assists with managing the overall symptom burden.

---

Quick Fact: Relief for Inflammation and Aches

МИГ 400 is relevant for managing symptom clusters that may become intense or disruptive, contributing to improved comfort during periods of heightened symptoms associated with joint stiffness and muscular strain.

Regulatory References

1. NIH MedlinePlus overview on Ibuprofen

Official Eligibility and Non-Eligibility for МИГ 400

The eligibility for using МИГ 400 (Ibuprofen 400 mg) is strictly defined by regulatory documents, establishing clear patient criteria for inclusion, restriction, and exclusion.

Category	Regulatory Status	Status Detail
Approved Age Group	Allowed	Adults and adolescents aged 12 years and above (or ge 40 kg body weight).
Pediatric Use	Not Recommended	Children under 12 years of age; lower dose strengths are designated for pediatric use.
Severe Organ Failure	Contraindicated	Prohibited for patients with severe hepatic failure, severe renal failure, or severe heart failure (e.g., NYHA Class IV).
Hypersensitivity	Contraindicated	Prohibited for patients with a history of allergic reactions (e.g., asthma, urticaria) after taking aspirin or other NSAIDs.
Pregnancy	Contraindicated	Prohibited during the third trimester of pregnancy (from 30 weeks gestation). Avoided from 20 weeks gestation onward.
Lactation	Generally Acceptable	Ibuprofen is found in very low concentration in breast milk and is unlikely to adversely affect the breast-fed infant.

Use is also contraindicated in the setting of peri-operative pain management for Coronary Artery Bypass Graft (CABG) surgery and for patients with active or recurrent gastrointestinal haemorrhage or peptic ulceration. Additionally, high daily doses (ge 2,400 mg) should be avoided in patients with established cardiovascular risks like uncontrolled hypertension or ischaemic heart disease.

Interaction Profile: Other Medicines and Products

The official regulatory profile for МИГ 400 (Ibuprofen) identifies interactions categorized by their effect on drug levels or by their additive physiological risk, strictly as documented in government labeling.

Category	Official Constraints & Interactions
Prohibited Combinations	Co-administration is formally contraindicated with other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and with high-dose Acetylsalicylic Acid (Aspirin).
Altered Drug Exposure	Ibuprofen is documented to reduce the renal clearance of substances such as Lithium and Methotrexate, leading to increased plasma concentrations and potential toxicity. Conversely, co-administration with CYP2C9 enzyme inhibitors is documented to increase the plasma exposure of Ibuprofen itself.
Additive Risk & Antagonism	A pharmacodynamic reinforcement occurs with Anticoagulants, SSRIs, and Corticosteroids, increasing the documented risk of hemorrhage or gastrointestinal damage. The efficacy of Antihypertensives and Diuretics is officially documented to be reduced, and this combination carries a heightened risk of renal impairment in the elderly or volume-depleted patients.
Timing Separation	For patients taking low-dose immediate-release Aspirin, a mandatory timing rule applies: МИГ 400 must be administered at least eight hours before or 30 minutes after the Aspirin dose to avoid interfering with its antiplatelet effect.

This structure reflects constraints based on dose, formulation, and patient condition, as defined in government regulatory information.

Molecular Target Inhibition of the Cyclooxygenase (COX) Enzymes

The primary mechanism of action involves the reversible inhibition of Cyclooxygenase (COX) enzymes, specifically both COX-1 and COX-2. By acting as a competitive inhibitor, the drug prevents these enzymes from converting Arachidonic Acid into Prostaglandin H2 (PGH2), the molecular precursor to pro-inflammatory and pyretic mediators. This action modifies the subsequent physiological cascade by directly suppressing the synthesis of PGE2 at the earliest molecular step.

---

️ Mechanism of Central Thermoregulatory Adjustment

The drug modulates the thermoregulatory signaling cascade that establishes an elevated central set point by acting on the hypothalamus, the brain’s temperature control center. Inhibition of COX-2 in this central region reduces the local synthesis of PGE2, which is the primary signaling molecule that resets the body's internal thermostat to a higher setting. This direct central intervention influences the activity within the thermoregulatory pathway, resulting in a physiological decrease in the elevated thermal set point.

---

Constraint via Non-Selective Enzyme Interaction

The mechanism's functional limitations arise from the unavoidable non-selective inhibition of the constitutive COX-1 enzyme alongside the inducible COX-2. While COX-2 inhibition mediates the intended physiological responses, COX-1 inhibition interferes with the enzyme's essential "housekeeping" role in producing prostanoids that maintain the integrity of the gastric lining and regulate renal function. This constraint frames the overall boundaries of the drug's mechanism of action.

How МИГ 400 is Used: Administration Guidelines

МИГ 400 (Ibuprofen 400 mg film-coated tablets) is intended for oral administration as a ready-to-use solid dosage form.

---

Dosing and Scheduling

The standard single dose of Ibuprofen for an adult is typically 400 mg. The maximum daily dose for non-prescription use is 1200 mg (three 400 mg doses) within a 24-hour period. Dosing is taken on an as-needed basis for acute symptoms, with a minimum interval of 6 hours between each 400 mg administration to maintain proper scheduling.

Administration Scope	Requirement
Route of Administration	Oral only
Maximum Single Dose	400 mg
Maximum Daily Dose	1200 mg (non-prescription)
Minimum Interval	6 hours between 400 mg doses

---

Administration Conditions and Duration

The tablets are to be swallowed whole with a glass of water and are generally taken with or immediately after food to minimize potential gastrointestinal discomfort.

Usage is limited to short-term courses. For self-care, use is typically restricted to 3 consecutive days for fever or 4 consecutive days for pain; if symptoms persist beyond this duration, a medical professional is consulted. For older adults, the general approach is to use the lowest effective dose for the shortest possible duration. If a dose is missed, the practice is not to double the next dose, but to take the next scheduled dose only after the full minimum interval has passed.

Research evidence / Overview of studies for МИГ 400

Evidence for Use in Acute Mild-to-Moderate Pain

The scope of research for the active ingredient in МИГ 400 includes its evaluation for conditions associated with acute or disruptive episodes, such as headache, dental discomfort, and general musculoskeletal aches. The research mainly consists of short-term Randomized Controlled Trials (RCTs) and comprehensive reviews that combined data from multiple studies. These trials were primarily relevant in evidence describing how symptoms are measured in adults and, separately, in children presenting with episodic or acute changes in discomfort.

Research has explored outcomes related to physical discomfort. Studies report how symptoms evolved in the observed populations, often measuring outcomes describing episodic or acute changes, like the intensity of discomfort and the time elapsed until a measured change was noted. Findings describe patterns observed in the studies where an evaluation of pain scores was conducted in the initial hours following administration, with research including comparisons against both placebo and specific alternative treatments.

It is important to note that follow-up durations were limited for this body of evidence, as the focus was on the immediate, short-term evaluation (measured in hours or days). Therefore, there is limited information for long-term outcomes following repeated use. Research exploring short-term symptom changes may also indicate that the level of change measured during the study period tends to reach a limit regardless of the administered dose, a pattern sometimes associated with an "analgesic ceiling."

---

Evidence for Use in Reducing Fever

Research explored the antipyretic activity of the active ingredient extensively in research contexts involving fluctuating or unstable symptoms, particularly in pediatric settings. Studies monitored outcomes related to systemic or functional imbalance, such as changes in core body temperature, and research included comparisons against specific antipyretic agents.

Trials examined how symptoms evolved in the observed populations, reporting data where a decrease in body temperature was evaluated within the first few hours post-administration. Research highlights changes measured during the study period, where measurements were reported to be maintained for several hours, with time-based measurements used to track persistence.

---

Long-Term Study Data and Evidence Gaps

For managing acute symptoms, the follow-up durations were limited, as research primarily examined short-term changes. Long-term effects are not fully established, particularly regarding repeated acute use. For chronic conditions, such as Osteoarthritis, research exploring long-term effects (e.g., over multiple years) often relies on observational settings, where evidence quality varies and data are still emerging.

Dedicated research exists evaluating children for acute pain and antipyretic activity. However, evidence is limited for individuals with complex health needs. Research describes that subgroup findings are uncertain regarding whether the effect profile differs significantly based on the specific type of pain being treated. Research provides insight into short-term changes, but does not determine whether an individual will respond similarly.

Key Studies & References Oral Analgesics for Acute Dental Pain (American Dental Association Guidelines)

Common questions about МИГ 400 (FAQ)

---

Q: What is the main difference between МИГ 400 and regular ibuprofen?

МИГ 400 contains the active substance ibuprofen. The main differences between a specific brand name product like МИГ 400 and generic ibuprofen may involve its formulation. This includes the presence of different inactive ingredients (excipients), the type of tablet coating, or the specific release speed, which is a choice made by the manufacturer.

---

Q: Is МИГ 400 safe to use for people with high blood pressure?

Official documentation advises that the use of ibuprofen can be associated with the development or worsening of hypertension (high blood pressure) and may reduce the effectiveness of some blood pressure medications. Regulatory documents state that use should be conducted with caution for patients with hypertension. High daily doses are generally advised to be avoided in this patient population due to documented risk.

---

Q: What are the most commonly reported side effects of МИГ 400?

Commonly reported, less severe side effects documented in official labeling typically include stomach pain, heartburn, nausea, vomiting, gas, constipation, or diarrhea. These effects are generally mild. Taking the medicine with food is officially recommended as a measure to help minimize the occurrence of potential gastrointestinal discomfort.

---

Q: Is it possible to develop a dependency on МИГ 400?

Ibuprofen is classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID) and is not generally associated with physical dependence or addiction like opioid medicines. However, official information highlights that the frequent or long-term use of painkillers for headaches may lead to a cycle of pain known as medication-overuse headache, which is one reason why official guidance emphasizes adherence to short-term use limits.

---

Q: Are there any known issues with taking МИГ 400 alongside coffee?

Official regulatory documents do not typically list coffee or caffeine as a specific prohibited interaction. While some pain relievers are manufactured to contain both ingredients, the documentation for all medicines generally advises caution with excessive caffeine intake, which is known to cause effects like nervousness or a fast heartbeat.

---

Q: Can МИГ 400 be used for pain relief from a toothache?

Yes, the active ingredient in МИГ 400 (ibuprofen) is officially indicated for the relief of pain associated with common conditions, which includes the symptomatic relief of dental pain or toothache. It works by addressing both the pain and the associated inflammation.

---

Q: Is МИГ 400 generally appropriate for treating menstrual pain?

Yes, regulatory documents often specify that the active ingredient in МИГ 400 (ibuprofen) is indicated for the symptomatic relief of pain associated with common conditions, including menstrual cramps (primary dysmenorrhea).

---

Q: Is МИГ 400 known to interact with birth control pills?

In general, NSAIDs like ibuprofen do not commonly interact with most oral contraceptives. However, regulatory documents indicate potential interaction concerns when ibuprofen is used with specific types of hormonal contraceptives (e.g., those containing drospirenone), which can increase the risk of elevated potassium levels. Caution is generally advised with prolonged use in these cases.

---

Q: Are there specific food items that should be avoided while using МИГ 400?

Official product labeling does not typically list specific foods that must be avoided. However, regulatory documents state that the tablets are generally recommended to be taken with or immediately after food to help minimize the risk of potential stomach irritation.

---

Q: Can МИГ 400 affect the results of common blood tests?

Regulatory documents note that the medicine's mechanism involves reversible inhibition of platelet function, which can affect certain blood clotting tests. Furthermore, it can affect certain laboratory values by altering kidney function or, rarely, liver enzyme levels, which may be detected during routine blood work.

---

Q: Is it normal to feel drowsy after taking МИГ 400?

Drowsiness (somnolence) and dizziness are listed in regulatory documents as uncommon side effects for the active ingredient. This means while they are recognized potential effects that some users may experience, they are not expected to occur in the majority of people.

---

Q: Does МИГ 400 contain any ingredients other than ibuprofen?

Yes. Like most medicines, МИГ 400 tablets contain inactive ingredients (excipients) in addition to the active substance, ibuprofen. These additional components are necessary for the tablet's structure, coating, and stability and are fully listed in the official product information.

---

Q: Is the composition of МИГ 400 similar to other non-steroidal anti-inflammatory drugs (NSAIDs)?

The active ingredient in МИГ 400, ibuprofen, belongs to the propionic acid derivative group of NSAIDs. This classification means it shares a common chemical structure and similar mechanism of action with other medicines in this specific sub-group of anti-inflammatory drugs.

---

Q: Are there any specific liver concerns mentioned in official documents regarding МИГ 400?

Official documents list severe hepatic failure (severe liver failure) as a contraindication, meaning the medicine should not be used in this condition. Additionally, official warnings note that liver function impairment is a recognized, though generally uncommon, risk associated with the use of the medicine.

---

Q: Why do some people use МИГ 400 for muscle soreness after exercise?

The active ingredient in МИГ 400 is officially indicated for the relief of various types of pain and inflammation, including musculoskeletal aches and muscle pain. It is therefore commonly used for the temporary relief of soreness and discomfort that can follow strenuous physical activity or exercise.

---

Q: What steps are generally recommended if a user experiences a severe side effect from МИГ 400?

Official patient instructions consistently advise that in the event a user experiences symptoms of a serious side effect, such as severe difficulty breathing, allergic reactions, or signs of internal bleeding (e.g., black or tarry stools), the medicine is generally recommended to be stopped, and emergency medical attention should be sought immediately.

---

Q: Does МИГ 400 lose its effectiveness if used too frequently?

Official regulatory evidence indicates that the efficacy of NSAIDs may reach an 'analgesic ceiling,' meaning that taking a higher dose may not provide significantly greater relief. Furthermore, continuous or frequent use of any headache medication can paradoxically contribute to the development of a medication-overuse headache.

---

Q: What are the indicators that МИГ 400 may not be suitable for a person?

Official documents outline several indicators, including a history of allergic-type reactions (such as asthma or hives) to aspirin or other NSAIDs, severe organ failure (heart, liver, or kidney), or active gastrointestinal bleeding or ulcers. Use is also contraindicated during the third trimester of pregnancy.

---

Q: Is there a risk of kidney issues described in official documentation for МИГ 400?

Yes, regulatory documentation advises that NSAID use can cause a worsening of existing kidney function or, rarely, lead to a decrease in kidney function. This risk is noted to be higher for older adults, patients with pre-existing kidney issues, or those who are taking diuretics or certain medications for high blood pressure.

---

Q: What are the different strengths or formats of МИГ 400 available?

While the name MИГ 400 specifically refers to the 400 mg strength, the active ingredient, ibuprofen, is widely available from various manufacturers in other strengths. These typically include lower over-the-counter doses like 200 mg and higher prescription-only strengths of 600 mg or 800 mg in some regions, often in different tablet or liquid formats.

---

Q: What are the differences between the pain relief mechanism of МИГ 400 and acetaminophen (paracetamol)?

МИГ 400 (ibuprofen) is an NSAID and primarily works throughout the body by inhibiting cyclooxygenase (COX) enzymes, which directly reduces inflammation. Acetaminophen (paracetamol) is not an NSAID and its mechanism is understood to be primarily central—acting in the brain and spinal cord to affect pain signals, with little to no anti-inflammatory effect on the body.

---

Q: Do studies support the use of МИГ 400 for tension-type headaches?

Official product information commonly indicates the active ingredient in МИГ 400 for the relief of pain associated with headaches. Regulatory documents specifically include its use for the symptomatic relief of mild to moderate tension headaches.

---

Q: Is it safe to drive a car after taking a regular amount of МИГ 400?

Official product information typically advises caution when driving or operating machinery. This is because side effects such as dizziness or drowsiness are possible, as documented in the undesirable effects section. It is generally advised that individuals observe how the medicine affects them personally before undertaking tasks that require full mental alertness.

---

Q: What types of pain are МИГ 400 not intended to treat?

The medicine is formally contraindicated for use in managing peri-operative pain immediately before or after coronary artery bypass graft (CABG) surgery. Its approved uses are generally limited to acute, mild-to-moderate pain and fever, and it is not typically intended for managing severe or chronic pain without professional medical supervision.

---

Q: Is there any research on МИГ 400's use in chronic pain conditions?

While the regulatory focus for over-the-counter use is on short-term relief, official documents mention that the active ingredient has been studied for long-term use in chronic inflammatory conditions. These include conditions such as rheumatoid arthritis or osteoarthritis, which often involve use at higher doses under the supervision of a healthcare professional.

---

Q: How quickly does МИГ 400 usually start to work?

According to official documentation, the onset of pain relief is typically described as beginning within 30 to 60 minutes following oral administration. Peak plasma levels, when the drug's concentration is highest in the blood, are generally achieved between one and two hours.

---

Q: How long can the pain relief from МИГ 400 be expected to last?

Official clinical and dosing information indicates that pain relief is generally expected to last for a duration of 4 to 6 hours following a single dose. This duration aligns with the recommended minimum interval between administrations for the 400 mg dose.

---

Q: Is there a maximum number of days МИГ 400 is intended to be used?

For self-treatment of acute symptoms without consulting a healthcare professional, the usage is limited. Official instructions state use should not exceed a maximum of 3 consecutive days for fever or 4 consecutive days for pain. Consultation is advised if symptoms persist beyond these time limits.

---

Q: Does taking МИГ 400 on an empty stomach increase the chance of side effects?

The official recommendation is to take the tablets with or immediately after food. This instruction is given to help minimize potential gastrointestinal discomfort or side effects. Taking the medicine on an empty stomach may increase the risk of these gastrointestinal issues.

---

Q: What should be done if a potential drug interaction with МИГ 400 is noticed?

If a potential drug interaction is noticed or suspected, such as unexpected side effects after combining medicines, official patient instructions consistently advise that if a potential interaction is suspected, consultation with a healthcare professional, such as a doctor or pharmacist, is generally recommended for evaluation.

---

Q: What information is available about using МИГ 400 in older adults?

Official documentation notes that older adults (age 60 years or older) are at an increased risk of experiencing serious gastrointestinal events. Regulatory guidance emphasizes using the lowest effective dose for the shortest possible duration of treatment when the medicine is used in this population.

---

Q: What are the main findings from clinical trials regarding МИГ 400?

Clinical trials support the measurable efficacy of the active ingredient in providing pain relief and reducing fever in acute, short-term conditions. Findings describe that a positive change in symptoms compared to placebo was generally conducted within the initial hours following administration, confirming its intended effects.

---

Q: Is the use of alcohol generally advised against while taking МИГ 400?

Yes. Official regulatory warnings advise against the consumption of alcohol while using the medicine. This combined use is documented to significantly increase the risk of stomach bleeding and overall gastrointestinal damage.

Storage and Disposal Requirements for МИГ 400

The storage of МИГ 400 (Ibuprofen 400 mg) must adhere strictly to the conditions detailed in regulatory labeling to maintain product stability and safety.

Official Storage Conditions

Requirement	Official Instruction
Temperature	Store at or below 25 C or 30 C at controlled room temperature, depending on the specific product label.
Protection	Protect from light and moisture by storing the medicine in its original outer carton.
Child Safety	Keep out of the sight and reach of children.

Handling and Disposal

The product should be kept in a tightly closed container where applicable and protected from excessive heat. Disposal of any unused or expired medicinal product must be conducted in accordance with local requirements for pharmaceutical waste, as the medicine may pose a risk to the environment.